
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc has demonstrated strong momentum in its core product, Cabometyx, particularly in the first-line renal cell carcinoma (RCC) and second-line neuroendocrine tumors (NET) markets, where it commands a 46% market share with a 15% year-over-year growth in total prescription volume. The company has strategically expanded its gastrointestinal sales team to capitalize on the growing demand for Cabometyx and prepare for the launch of zanzalintinib in colorectal cancer, bolstered by favorable results from the Phase 3 STELLAR-303 trial, which showed a statistically significant improvement in overall survival. Additionally, Exelixis's robust balance sheet and projections for increased Cabometyx sales—estimated to reach $2.8 billion by FY28—further underscore its potential for sustainable profitability and market leadership in oncology therapeutics.
Bears say
Exelixis Inc has reported a decline in its gross-to-net (GTN) from 30.2% in 3Q25 to 28.5% in 4Q25, primarily due to decreased PHS/340B volumes, raising concerns about revenue sustainability. Cabometyx sales reached $545 million in 4Q25, which was below both the company's and consensus estimates, contributing to an uncertain outlook for future growth in the increasingly competitive markets of renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Additionally, several risks jeopardize Exelixis's financial health, including potential commercial limitations for Cabometyx, the possibility of unfavorable data from ongoing clinical trials, generic erosion of its established franchises, and long-term dilution risks.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares